Gadoversetamide Gd-DTPA-BMEA
Il Gadoversetamide Gd-DTPA-BMEA è una molecola utilizzata per u mezzo di contrasto in risonanza magnetica. E' un prodotto non ionico.
Viene commercializzato come OptiMARK dalla Mallinckrodt Inc.
E' un mezzo di contrasto positivo in T1, con finestra utile di enhancement di almeno un ora dalla somministrazione.
Può essere utilizzato per le angio-RM a bolo.
[allegato non incluso]
Peso molecolare—
661.77
Densità
1.160 gm per mL at 25 °C.
Osmolarità
1110 mOsmol per kg of water at 37 °C (approximately 4 times the osmolality of plasma).
pH
5.5 to 7.5.
Viscosity
3.1 cP at 20 °C.
2.0 cP at 37 °C.
CitazioneWARNING
NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.
- Do not administer OptiMARK™ (gadoversetamide injection) to patients with:
- chronic, severe kidney disease (GFR < 30 mL/min/1.73m²), or
- acute kidney injury (see CONTRAINDICATIONS).
Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. Do not exceed the recommended OptiMARK™ (gadoversetamide injection) dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration (see WARNINGS).